Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4757 Skf-99101h Selective, brain penetrant 5-HT(1B/D) receptor agonist
DCC4758 Ski-349 Novel dual-targeted inhibitor of sphingosine kinase and microtubule polymerization
DCC4759 Ski-417616 Potent inhibitor of Dengue viruses (DENV), displaying activities against all four serotypes of DENV, as well as to a related flavivirus, West Nile virus (WNV), and an alphavirus, Sindbis virus (SINV)
DCC4760 S-kkwk Potent influenza A virus (IAV) entry inhibitor, targeting a conserved region of hemagglutinin
DCC4761 sklb023 Novel inhibitor of NF
DCC4762 Sklb028 Millepachine analog, inhibiting tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin
DCC4763 Sklb050 Biological Active Reagents
DCC4764 Sklb-163 Potent anticancer agent, downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK
DCC4765 Sklb-329 Novel multikinase inhibitor, potently inhibiting angiogenesis-related kinases including VEGFR1/2/3, and FGFR2, and the Src kinase
DCC4766 Sklb-677 Novel FLT3 and Wnt/β-catenin signaling inhibitor, displaying potent activity in models of FLT3-driven AML
DCC4767 Sklb70326 Novel inhibitor of cell-cycle progression, inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells
DCC4768 Skog102 Novel inhibitor of OLIG2 in glioblastoma
DCC4769 skp Inhibitor C16 Specific Inhibitor of Skp2-Mediated p27 Degradation
DCC4770 skp Inhibitor C20 Specific Inhibitor of Skp2-Mediated p27 Degradation
DCC4771 Skp2 Inhibitor C2 First-in-class Specific Inhibitor of Skp2-Mediated p27 Degradation
DCC4772 Sl-1-73 Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma
DCC4773 Sl-3-19 Novel microtubule-destabilizing agent, exerting potent antitumor activity against esophageal squamous cell carcinoma
DCC4774 Sl-651498 Full agonist of GABAA receptors containing α2 and α3 subunits, and partial agonist of α1 and α5 subunits.
DCC4775 Sl910102 Novel nonpeptide AT1 receptor antagonist, acting as a modulator on RAAS and KKS activation during COVID-19
DCC4776 Slec-8 Potential synthetic lethal lead, targeting E-cadherin-deficient cells
DCC4777 Slk/stk10-in-31 Novel Potent Dual inhibitor of SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10)
DCC4778 Sll-039 Novel highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/μ = 682, κ/δ = 283)
DCC4779 Slm6071469 Novel potent SphK2-selective inhibitor (Ki = 89 nM, 73-fold SphK2-selective) with validated in vivo activity
DCC4780 Slp120701 Novel SphK2-selective inhibitor with improved half-life to 8 h in mice
DCC4781 Slp7111228 Novel selective SphK1 inhibitor
DCC4782 Slr080811 Novel SphK2-selective inhibitor
DCC4783 Slupp-225 Novel efflux pump inhibitor (EPI)
DCC4784 Slupp-417 Novel efflux pump inhibitor (EPI)
DCC4785 Sm-130686 Potent, orally-active agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) and growth hormone secretagogue
DCC4786 Sm-131 Novel Potent, Cell-Permeable, Conformationally Constrained Second Mitochondria Derived Activator of Caspase (Smac) Mimetic

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X